## MK-0608

Cat. No.:	HY-10244		
CAS No.:	443642-29-	3	
Molecular Formula:	$C_{12}H_{16}N_{4}O_{4}$		
Molecular Weight:	280.28		
Target:	HCV		
Pathway:	Anti-infecti	on	
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (891.97 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	3.5679 mL	17.8393 mL	35.6786 mL		
		5 mM	0.7136 mL	3.5679 mL	7.1357 mL		
		10 mM	0.3568 mL	1.7839 mL	3.5679 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (7.42 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (7.42 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (7.42 mM); Clear solution						

BIOLOGICAL ACTIV	
BIOLOGICAL ACTIV	
Description	MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC <sub>50</sub> of 0.3 μM (EC <sub>90</sub> =1.3 μM) in the subgenomic-replicon assay <sup>[1]</sup> .
IC <sub>50</sub> & Target	EC50: 0.3 μM (HCV replication) <sup>[1]</sup>
In Vivo	Oral dosing of MK-0608 results in a potent antiviral effect. In preclinical pharmacokinetic experiments with rats, dogs, and rhesus monkeys, MK-0608 demonstrates good to excellent oral bioavailability (50 to 100%) and long plasma half-lives in

## Product Data Sheet

OH OH

HO

 $\mathrm{NH}_2$ 

Ν

N



dogs and rhesus macad MCE has not independe	<b>ques (9 and 14 h, respectively)</b> <sup>[1]</sup> . ently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	The HCV-infected chimpanzees <sup>[1]</sup>
Dosage:	1 mg/kg
Administration:	Administered orally; once daily for 37 days
Result:	Chimpanzee X6 had a baseline viral load that varied from 1,110 to 12,900 IU/mL, and chimpanzee X4 had a baseline viral load of 3×10 <sup>6</sup> to 9×10 <sup>6</sup> IU/mL.

## REFERENCES

[1]. Carroll SS, et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother. 2009 Mar;53(3):926-34.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA